New pill INX-315 takes on advanced breast and ovarian cancers
NCT ID NCT05735080
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is to check safety, find the right dose, and see if it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INX-315 (an oral drug), sometimes combined with fulvestrant or abemaciclib
What this could lead to
If it works, this could provide a new treatment option for people with advanced breast or ovarian cancer that has stopped responding to standard therapies.
What could go wrong
This is an early first-in-human study, so safety and effectiveness are not yet proven. It may not work for all participants, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Email: •••••@•••••
-
Duke Cancer Center/ DUMC
RECRUITINGDurham, North Carolina, 27705, United States
Contact
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact
Contact Email: •••••@•••••
-
Fort Wayne Medical Oncology and Hematology
RECRUITINGFort Wayne, Indiana, 46804, United States
Contact Email: •••••@•••••
Contact
-
Gabrail Cancer Research Center
RECRUITINGCanton, Ohio, 44718, United States
Contact Email: •••••@•••••
Contact
-
Georgia Cancer Center at Augusta University
RECRUITINGAugusta, Georgia, 30912, United States
Contact Email: •••••@•••••
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Levine Cancer Institute (LCI)- Atrium Health
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
-
Mater Hospital
RECRUITINGSouth Brisbane, 4101, Australia
Contact
-
Next Oncology
RECRUITINGDallas, Texas, 75039, United States
Contact Email: •••••@•••••
Contact
-
Next Oncology
RECRUITINGHouston, Texas, 77054, United States
Contact Email: •••••@•••••
Contact
-
Northwest Medical Specialties, PLLC
RECRUITINGTacoma, Washington, 98405, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oncology Consultants
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peninsula and South Eastern Haematology & Oncology Group
RECRUITINGFrankston, Victoria, 3199, Australia
Contact Email: •••••@•••••
Contact
-
Peter MacCallum Cancer Center
RECRUITINGParkville, Victoria, 3052, Australia
Contact
Contact Email: •••••@•••••
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UTSW Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Email: •••••@•••••